MNKD Projected Dividend Yield
MannKind Corp ( NASDAQ : MNKD )MannKind is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Co.'s primary product, Afrezza (insulin human) Inhalation Powder, is an inhaled insulin indicated to improve glycemic control in adults with diabetes. Afrezza consists of a dry powder formulation of human insulin delivered from a small portable inhaler. Co. collaborates with United Therapeutics to develop an inhaled formulation of treprostinil known as Tyvaso DPI. 20 YEAR PERFORMANCE RESULTS |
MNKD Dividend History Detail MNKD Dividend News MNKD Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |